News >

Forde Forecasts Future Use of Immunotherapy in Early-Stage NSCLC

Caroline Seymour
Published: Thursday, Jan 03, 2019

Patrick M. Forde, MBBCh

Patrick M. Forde, MBBCh

Immunotherapy has demonstrated significant activity in patients with metastatic non–small cell lung cancer (NSCLC), noted Patrick M. Forde, MBBCh, with a slow transition to its use in the early-stage setting for those with resectable and unresectable lung disease.

The clinical benefit of immunotherapy has also been observed in patients with resectable disease, said Forde. In a small phase II study, neoadjuvant nivolumab (Opdivo) demonstrated a pathological response in 45% of patients whose tumors were completely resected in surgery (NCT02259621).3,4

Investigators believe that research with established and emerging biomarkers such as PD-L1, tumor mutational burden (TMB), and gene signatures will help identify patients with the highest chance of response to treatment. However, Forde explained that challenges remain in making immunotherapy available to those with early-stage disease.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication